Value of SERCA2a as a Biomarker for the Identification of Patients with Heart Failure Requiring Circulatory Support

Background: Heart failure (HF) alters the nucleo-cytoplasmic transport of cardiomyocytes and reduces SERCA2a levels, essential for intracellular calcium homeostasis. We consider in this study whether the molecules involved in these processes can differentiate those patients with advanced HF and the...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Meryem Ezzitouny, Esther Roselló-Lletí, Manuel Portolés, Ignacio Sánchez-Lázaro, Miguel Ángel Arnau-Vives, Estefanía Tarazón, Carolina Gil-Cayuela, Silvia Lozano-Edo, Raquel López-Vilella, Luis Almenar-Bonet, Luis Martínez-Dolz
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	heart failure nucleocytoplasmic transport heart transplantation mechanical circulatory support SERCA2a biomarkers Medicine R
Acceso en línea:	https://doaj.org/article/0ca13a5982634a3ba4eab7e3bff02a58
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:0ca13a5982634a3ba4eab7e3bff02a58
record_format	dspace
spelling	oai:doaj.org-article:0ca13a5982634a3ba4eab7e3bff02a582021-11-25T18:07:22ZValue of SERCA2a as a Biomarker for the Identification of Patients with Heart Failure Requiring Circulatory Support10.3390/jpm111111222075-4426https://doaj.org/article/0ca13a5982634a3ba4eab7e3bff02a582021-10-01T00:00:00Zhttps://www.mdpi.com/2075-4426/11/11/1122https://doaj.org/toc/2075-4426Background: Heart failure (HF) alters the nucleo-cytoplasmic transport of cardiomyocytes and reduces SERCA2a levels, essential for intracellular calcium homeostasis. We consider in this study whether the molecules involved in these processes can differentiate those patients with advanced HF and the need for mechanical circulatory support (MCS) as a bridge to recovery or urgent heart transplantation from those who are clinically stable and who are transplanted in an elective code. Material and method: Blood samples from 29 patients with advanced HF were analysed by ELISA, and the plasma levels of Importin5, Nucleoporin153 kDa, RanGTPase-Activating Protein 1 and sarcoplasmic reticulum Ca<sup>2+</sup> ATPase were compared between patients requiring MCS and those patients without a MCS need prior to heart transplantation. Results: SERCA2a showed significantly lower levels in patients who had MCS compared to those who did not require it (0.501 ± 0.530 ng/mL vs. 1.123 ± 0.661 ng/mL; <i>p</i> = 0.01). A SERCA2a cut-off point of 0.84 ng/mL (AUC 0.812 ± 0.085, 95% CI: 0.646–0.979; <i>p</i> = 0.004) provided a 92% sensitivity, 62% specificity, 91% negative predictive value and 67% positive predictive value. Conclusions: In this cohort, patients with advanced HF and a need for MCS have shown significantly lower levels of SERCA2a as compared to stable patients without a need for MCS prior to heart transplantation. This is a small study with preliminary findings, and larger-powered dedicated studies are required to confirm and validate these results.Meryem EzzitounyEsther Roselló-LletíManuel PortolésIgnacio Sánchez-LázaroMiguel Ángel Arnau-VivesEstefanía TarazónCarolina Gil-CayuelaSilvia Lozano-EdoRaquel López-VilellaLuis Almenar-BonetLuis Martínez-DolzMDPI AGarticleheart failurenucleocytoplasmic transportheart transplantationmechanical circulatory supportSERCA2abiomarkersMedicineRENJournal of Personalized Medicine, Vol 11, Iss 1122, p 1122 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	heart failure nucleocytoplasmic transport heart transplantation mechanical circulatory support SERCA2a biomarkers Medicine R
spellingShingle	heart failure nucleocytoplasmic transport heart transplantation mechanical circulatory support SERCA2a biomarkers Medicine R Meryem Ezzitouny Esther Roselló-Lletí Manuel Portolés Ignacio Sánchez-Lázaro Miguel Ángel Arnau-Vives Estefanía Tarazón Carolina Gil-Cayuela Silvia Lozano-Edo Raquel López-Vilella Luis Almenar-Bonet Luis Martínez-Dolz Value of SERCA2a as a Biomarker for the Identification of Patients with Heart Failure Requiring Circulatory Support
description	Background: Heart failure (HF) alters the nucleo-cytoplasmic transport of cardiomyocytes and reduces SERCA2a levels, essential for intracellular calcium homeostasis. We consider in this study whether the molecules involved in these processes can differentiate those patients with advanced HF and the need for mechanical circulatory support (MCS) as a bridge to recovery or urgent heart transplantation from those who are clinically stable and who are transplanted in an elective code. Material and method: Blood samples from 29 patients with advanced HF were analysed by ELISA, and the plasma levels of Importin5, Nucleoporin153 kDa, RanGTPase-Activating Protein 1 and sarcoplasmic reticulum Ca<sup>2+</sup> ATPase were compared between patients requiring MCS and those patients without a MCS need prior to heart transplantation. Results: SERCA2a showed significantly lower levels in patients who had MCS compared to those who did not require it (0.501 ± 0.530 ng/mL vs. 1.123 ± 0.661 ng/mL; <i>p</i> = 0.01). A SERCA2a cut-off point of 0.84 ng/mL (AUC 0.812 ± 0.085, 95% CI: 0.646–0.979; <i>p</i> = 0.004) provided a 92% sensitivity, 62% specificity, 91% negative predictive value and 67% positive predictive value. Conclusions: In this cohort, patients with advanced HF and a need for MCS have shown significantly lower levels of SERCA2a as compared to stable patients without a need for MCS prior to heart transplantation. This is a small study with preliminary findings, and larger-powered dedicated studies are required to confirm and validate these results.
format	article
author	Meryem Ezzitouny Esther Roselló-Lletí Manuel Portolés Ignacio Sánchez-Lázaro Miguel Ángel Arnau-Vives Estefanía Tarazón Carolina Gil-Cayuela Silvia Lozano-Edo Raquel López-Vilella Luis Almenar-Bonet Luis Martínez-Dolz
author_facet	Meryem Ezzitouny Esther Roselló-Lletí Manuel Portolés Ignacio Sánchez-Lázaro Miguel Ángel Arnau-Vives Estefanía Tarazón Carolina Gil-Cayuela Silvia Lozano-Edo Raquel López-Vilella Luis Almenar-Bonet Luis Martínez-Dolz
author_sort	Meryem Ezzitouny
title	Value of SERCA2a as a Biomarker for the Identification of Patients with Heart Failure Requiring Circulatory Support
title_short	Value of SERCA2a as a Biomarker for the Identification of Patients with Heart Failure Requiring Circulatory Support
title_full	Value of SERCA2a as a Biomarker for the Identification of Patients with Heart Failure Requiring Circulatory Support
title_fullStr	Value of SERCA2a as a Biomarker for the Identification of Patients with Heart Failure Requiring Circulatory Support
title_full_unstemmed	Value of SERCA2a as a Biomarker for the Identification of Patients with Heart Failure Requiring Circulatory Support
title_sort	value of serca2a as a biomarker for the identification of patients with heart failure requiring circulatory support
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/0ca13a5982634a3ba4eab7e3bff02a58
work_keys_str_mv	AT meryemezzitouny valueofserca2aasabiomarkerfortheidentificationofpatientswithheartfailurerequiringcirculatorysupport AT estherrosellolleti valueofserca2aasabiomarkerfortheidentificationofpatientswithheartfailurerequiringcirculatorysupport AT manuelportoles valueofserca2aasabiomarkerfortheidentificationofpatientswithheartfailurerequiringcirculatorysupport AT ignaciosanchezlazaro valueofserca2aasabiomarkerfortheidentificationofpatientswithheartfailurerequiringcirculatorysupport AT miguelangelarnauvives valueofserca2aasabiomarkerfortheidentificationofpatientswithheartfailurerequiringcirculatorysupport AT estefaniatarazon valueofserca2aasabiomarkerfortheidentificationofpatientswithheartfailurerequiringcirculatorysupport AT carolinagilcayuela valueofserca2aasabiomarkerfortheidentificationofpatientswithheartfailurerequiringcirculatorysupport AT silvialozanoedo valueofserca2aasabiomarkerfortheidentificationofpatientswithheartfailurerequiringcirculatorysupport AT raquellopezvilella valueofserca2aasabiomarkerfortheidentificationofpatientswithheartfailurerequiringcirculatorysupport AT luisalmenarbonet valueofserca2aasabiomarkerfortheidentificationofpatientswithheartfailurerequiringcirculatorysupport AT luismartinezdolz valueofserca2aasabiomarkerfortheidentificationofpatientswithheartfailurerequiringcirculatorysupport
_version_	1718411601365696512

Value of SERCA2a as a Biomarker for the Identification of Patients with Heart Failure Requiring Circulatory Support

Ejemplares similares